December 5, 2015 – A safety review by the American Food and Drug Administration (FDA) has resulted in the addition of specific warnings to the drug labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors …

SGLT2 Inhibitors and ketoacidosis: Warnings about too much acid in the blood and serious urinary tract infections included in new drug labels Read more »

December 02, 2015 –  The American Food and Drug Administration (FDA) just granted approval for Elotuzumab (Empliciti) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Elotuzumab (Empliciti) is a monoclonal …

Elotuzumab (Empliciti), a new immune-stimulating therapy to treat multiple myeloma has been approved Read more »

November 28, 2015 – The American Food and Drug Administration (FDA) just approved Necitumumab (Portrazza) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication …

Necitumumab (Portrazza) approved for the treatment of advanced squamous non-small cell lung cancer (NSCLC) Read more »

November 25, 2015 – Right in time for the upcoming holyday season, this post addresses once more the issue of tainted sexual enhancement products. Such products, bought over the counter (OTC) or from Internet stores may pose serious health risks …

Stiff Nights: Dangerously tainted sexual enhancement products are everywhere Read more »

November 21, 2015 – During the last few days, the American Food and Drug Administration  (FDA) just extended the armamentarium in the fight against multiple myeloma by two new entries, namely Ixazomib (Ninlaro) and Daratumumab (Darzalex). Both drugs are intended to treat …

FDA extends armamentarium to treat multiple myeloma: Ixazomib (Ninlaro) and Daratumumab (Darzalex) approved Read more »

November 14, 2015 – The American Food and Drug Administration (FDA) just granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso) was approved for patients whose tumors have a specific …

Theragenomic medicine: FDA approves Osimertinib (Tagrisso) to treat patients with non-small cell lung cancer (NSCLC) who carry the EGFR mutation T790M Read more »

November 13, 2015 – The American Food and Drug Administration (FDA) just approved Cobimetinib (Cotellic) to be used in combination with Vemurafenib (Zelboraf) to treat advanced melanoma that has spread to other parts of the body or can’t be removed by …

Cobimetinib (Cotellic) is now approved as part of a combination treatment with Vemurafenib (Zelboraf) for advanced melanoma Read more »

November 06, 2015 – Just about the same time at the End of October 2015, the American Drug and Food Administration (FDA) has approved, and the European Medicines Agency (EMA) has recommended for approval Talimogene Laherparepvec (Imlygic), a first-in-class advanced therapy medicinal product (ATMP) derived from a …

Imlygic, a first-of-its-kind oncolytic immunotherapy for the treatment of melanoma Read more »

October 28, 2015 – According to a  small prospective and randomized clinical study, just published online in the Annals of Internal Medicine, a regularly taken glass of wine with dinner may improve lipid and glycemic control profiles in patients with type 2 …

Theragenomic medicine and social habits: A regularly taken glass of wine may improve cardiometabolic risks in some patients with type 2 diabetes Read more »

October 24, 2015 –  The Amrican Food and Drug Administration approved Trabectedin (Yondelis) for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen. The approval of trabectedin is based on improvement in progression-free survival (PFS) in a multicenter, …

Trabectedin (Yondelis) approved by the FDA for unresectable or metastatic liposarcoma or leiomyosarcoma Read more »